Mast cells (MCs) are involved in several biological processes, such as defense against pathogens, immunomodulation, tissue repair after injury, and angiogenesis. MCs have been shown to change from protective immune cells to potent pro-inflammatory cells, influencing the progression of many pathological conditions, including autoimmune diseases and cancers. The role of MCs in the pathogenesis of rhinopathies has often been underestimated, since previous studies have focused their attention on eosinophils and neutrophils, while MCs were considered involved exclusively in allergic rhinitis. However, recent nasal cytology findings have shown the involvement of MCs in several rhinopathies, such as NARMA, NARESMA, and CRSwNP. These recent evidences highlight the crucial role that MCs play in orchestrating the inflammation of the nasal mucosa, through complex biological mechanisms, not yet fully understood. In this context, a better understanding of these mechanisms is fundamental for practicing Precision Medicine, which requires careful population selection and stratification into subgroups based on the phenotype/endotype of the patients, in order to guarantee the patient a tailored therapy. Based on this background, further studies are needed to understand the pathophysiological mechanisms involving MCs and, consequently, to develop targeted therapies aimed to obtain a selective inhibition of tissue remodeling and preventing MC-mediated immune suppression.

Keywords:
Nasal cytology, Mast cells, Rhinopathies, Chronic rhinosinusitis with nasal polyps, Rhinitis
1.
Crivellato E, Beltrami CA, Mallardi F, Ribatti D. Paul Ehrlich’s doctoral thesis: a milestone in the study of mast cells.
Br J Haematol
. 2003 Oct;123(1):19–21.
2.
Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: a multi-functional master cell.
Front Immunol
. 2016 Jan 6;6:620.
3.
Metcalfe DD, Boyce JA. Mast cell biology in evolution.
J Allergy Clin Immunol
. 2006 Jun;117(6):1227–9.
4.
Ribatti D, Crivellato E. The controversial role of mast cells in tumor growth.
Int Rev Cell Mol Biol
. 2009;275:89–131.
5.
Weller K, Foitzik K, Paus R, Syska W, Maurer M. Mast cells are required for normal healing of skin wounds in mice.
FASEB J
. 2006;20(13):2366–8.
6.
Maurer M, Theoharides T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, et al. What is the physiological function of mast cells?
Exp Dermatol
. 2003 Dec;12(6):886–910.
7.
Collington SJ, Williams TJ, Weller CL. Mechanisms underlying the localisation of mast cells in tissues.
Trends Immunol
. 2011 Oct;32(10):478–85.
8.
Balzar S, Chu HW, Strand M, Wenzel S. Relationship of small airway chymase-positive mast cells and lung function in severe asthma.
Am J Respir Crit Care Med
. 2005;171(5):431–9.
9.
Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites: fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content.
Pathol Res Pract
. 1993;189(2):156–62.
10.
Andersson CK, Mori M, Bjermer L, Löfdahl CG, Erjefält JS. Novel site-specific mast cell subpopulations in the human Lung.
Thorax
. 2009;64(4):297–305.
11.
Irani AMA, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MC(T) and MC(TC) types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies.
J. Histochem. Cytochem
. 1989;37(10):1509–15.
12.
Hofmann AM, Abraham SN. New roles for mast cells in modulating allergic reactions and immunity against pathogens.
Curr Opin Immunol
. 2009 Dec;21(6):679–86.
13.
Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al. Rhinitis 2020: a practice parameter update.
J Allergy Clin Immunol
. 2020 Oct;146(4):721–67.
14.
Gelardi M, Iannuzzi L, Quaranta N, Landi M, Passalacqua G. NASAL cytology: practical aspects and clinical relevance.
Clin Exp Allergy
. 2016 Jun;46(6):785–92.
15.
Gelardi M, Maselli del Giudice A, Fiorella ML, Fiorella R, Russo C, Soleti P, et al. Non-allergic rhinitis with eosinophils and mast cells constitutes a new severe nasal disorder.
Int J Immunopathol Pharmacol
. 2008;21(2):325–31.
16.
Ribatti D, Crivellato E. Mast cells, angiogenesis, and tumour growth.
Biochim Biophys Acta
. 2012 Jan;1822(1):2–8.
17.
Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor.
J Clin Invest
. 1997 Jun;99(11):2691–700.
18.
McHale C, Mohammed Z, Gomez G. Human skin-derived mast cells spontaneously secrete several angiogenesis-related factors.
Front Immunol
. 2016 Jun 25;10:1445.
19.
Ohkubo K, Ikeda M, Pawankar R, Gotoh M, Yagi T, Okuda M. Mechanisms of IL-6, IL-8, and GM-CSF release in nasal secretions of allergic patients after nasal challenge.
Rhinology
. 1998 Dec;36(4):156–61.
20.
Matsune S. Allergic rhinitis and vascular endothelial growth factor.
J Nippon Med Sch
. 2012;79(3):170–5.
21.
He J, Wang T, Yao L, Chen A, Zhou B, Yu H, et al. Construction and delivery of gene therapy vector containing soluble TNFalpha receptor-IgGFc fusion gene for the treatment of allergic rhinitis.
Cytokine
. 2006 Dec;36(5–6):296–304.
22.
Hu B, Zhao S, Huang M, Ren J. Nuclear factor e2 related factor (Nrf2) inhibits mast cell-mediated allergic inflammation via sirt4-mediated mitochondrial metabolism.
Ann Palliat Med
. 2020 Nov;9(6):3839–47.
23.
Backaert W, Steelant B, Hellings PW, Talavera K, Van Gerven L. A TRiP through the roles of transient receptor potential cation channels in type 2 upper airway inflammation.
Curr Allergy Asthma Rep
. 2021 Mar 18;21(3):20.
24.
Tomljenovic D, Baudoin T, Megla ZB, Geber G, Scadding G, Kalogjera L. Females have stronger neurogenic response than males after non-specific nasal challenge in patients with seasonal allergic rhinitis.
Med Hypotheses
. Jul. 2018;116:114–8.
25.
Gelardi M, Russo C, Fiorella ML, Fiorella R, Canonica GW, Passalacqua G. When allergic rhinitis is not only allergic.
Am J Rhinol Allergy
. 2009;23(3):312–5.
26.
Kawakami T, Kasakura K Mast Cell eavesdropping on bacterial communications.
Cell Host Microbe
. 2019 Jul 10;26(1):3–5.
27.
Piliponsky AM, Acharya M, Shubin NJ. Mast cells in viral, bacterial, and fungal infection immunity.
Int J Mol Sci
. 2019 Jun 12;20(12):2851.
28.
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020.
Rhinology
. 2020 Feb;58(Suppl S29):1–464.
29.
Cao PP, Zhang YN, Liao B, Ma J, Wang BF, Wang H, et al. Increased local IgE production induced by common aeroallergens and phenotypic alteration of mast cells in Chinese eosinophilic, but not non-eosinophilic, chronic rhinosinusitis with nasal polyps.
Clin Exp Allergy
. 2014;44(5):690–700.
30.
Dwyer DF, Ordovas-Montanes J, Allon SJ, Buchheit KM, Vukovic M, Derakhshan T, et al. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation.
Sci Immunol
. 2021;6(56):eabb7221.
31.
Zhai GT, Li JX, Zhang XH, Liao B, Lu X, Liu Z. Increased accumulation of CD30 ligand-positive mast cells associates with eosinophilic inflammation in nasal polyps.
LaryngoscopeMar
. 2019;129(3):E110.
32.
Takabayashi T, Schleimer RP. Formation of nasal polyps: the roles of innate type 2 inflammation and deposition of fibrin.
J Allergy Clin Immunol
. 2020 Mar;145(3):740–50.
33.
Zhai GT, Wang H, Li JX, Cao PP, Jiang WX, Song J, et al. IgD-activated mast cells induce IgE synthesis in B cells in nasal polyps.
J Allergy Clin Immunol
. 2018;142(5):1489–e23.
34.
Belsky MA, Corredera E, Banerjee H, Moore J, Wang L, Kane LP, et al. Association of mast cell burden and tim-3 expression with recalcitrant chronic rhinosinusitis with nasal polyps.
Ann Otol Rhinol Laryngol
. 2021;130(9):1069.
35.
Corredera E, Phong BL, Moore JA, Kane LP, Lee SE. TIM-3-Expressing Mast Cells are present in chronic rhinosinusitis with nasal polyps.
Otolaryngol Head Neck Surg
. Sep. 2018;159(3):581–6.
36.
Hayes SM, Biggs TC, Goldie SP, Harries PG, Walls AF, Allan RN, et al. Staphylococcus aureus internalization in mast cells in nasal polyps: characterization of interactions and potential mechanisms.
J Allergy Clin Immunol
. 2020;145(1):147–59.
37.
Gelardi M, Russo C, Fiorella ML, Fiorella R, Ciprandi G. Inflammatory cell types in nasal polyps.
Cytopathology
. 2010 Jun;21(3)201–3.
38.
Gelardi M, Porro G, Quaranta V, Quaranta N, Cassano M, Ciprandi G, et al. Clinical-cytological-grading and phenotyping in patients with chronic rhinosinusitis with nasal polyps: the relevance in clinical practice.
Monaldi Arch Chest Dis
. 2020;90(2):348–52.
39.
Liva GA, Karatzanis AD, Prokopakis EP. Review of rhinitis: classification, types, pathophysiology.
J Clin Med
. 2021 Jul;10(14):3183.
40.
Gelardi M, Giancaspro R, Pecoraro P, Cassano M. Nasal cytology in allergic rhinitis: rare observation of pollen degranulation.
Int Forum Allergy Rhinol
. 2021 Jun 29.
41.
Gelardi M. “Overlapped” rhinitis: a real trap for rhinoallergologists.
Eur Annals Allergy clin immunol
.2014 Nov;46(6):234–6.
42.
Gelardi M, Iannuzzi L, De Giosa M, Taliente S, De Candia N, Quaranta N, et al. Non-surgical management of chronic rhinosinusitis with nasal polyps based on clinical-cytological grading: a precision medicine-based approach.
Acta Otorhinolaryngol Ital
. 2017 Feb;37(1):38–45.
43.
Hellings PW, Verhoeven E, Fokkens WJ. State-of-the-art overview on biological treatment for CRSwNP.
Rhinol J
. 2021 Apr 1;9(2):151–63.
© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.